Claims
- 1. A polyamine having the structure
- 2. A polyamine having the structure
- 3. A polyamine having the structure
- 4. A polyamine having the structure
- 5. A polyamine having the structure
- 6. The polyamine of any one of claims 1-5, wherein said structure is that of compounds A-Q, T and U as shown in FIG. 1.
- 7. A pharmaceutical composition useful for treating a disease or condition in which the inhibition of cell growth or proliferation is desirable, comprising a polyamine according to any one of claims 1-6 and a pharmaceutically acceptable excipient, diluent or vehicle.
- 8. The composition of claim 7 wherein said excipient, diluent or vehicle is pharmaceutically or cosmetically acceptable.
- 9. The composition of claim 7 wherein said excipient, diluent or vehicle is for topical or intra-aural administration.
- 10. The composition of claim 7 formulated for intravenous, subcutaneous, intramuscular, intracranial, intraperitoneal, topical, transdermal, intravaginal, intranasal, intrabronchial, intracranial, intraocular, intraaural, rectal, or parenteral administration.
- 11. A method of treating one or more conditions associated with cellular proliferation comprising administration of a polyamine represented by at least one of the following structures:
- 12. The method of claim 11 wherein said administration is systemic.
- 13. The method of claim 11 wherein said administration is oral.
- 14. The method of claim 11 wherein said administration is via a time-release vehicle.
- 15. A method of inhibiting hair growth comprising topical administration to a subject in need of hair growth inhibition of a polyamine represented by at least one of the following structures:
- 16. The method of claim 15 wherein polyamine is formulated as a cosmetic.
- 17. A method of inhibiting hair loss (alopecia) comprising topical administration of a subject undergoing radiation or chemotherapy a polyamine represented by at lest one of the following structures:
- 18. A method of treating fungal, bacterial, viral and parasitic agents, comprising administration of a polyamine represented by at least one of the following structures:
- 19. A method according to claim 11 wherein said condition is selected from the group consisting of cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease and other inflammatory bowel diseases.
- 20. A method of treating one or more conditions associated with cellular proliferation comprising administration of at least one of B, T or U shown in FIG. 1.
- 21. The method of claim 20 wherein said administration is systemic.
- 22. The method of claim 20 or 21 wherein said administration is oral.
- 23. The method of claim 20 or 21 wherein said administration is via a time-release vehicle.
- 24. A method of inhibiting hair growth comprising topical administration of at least one of B, T or U shown in FIG. 1 to a subject in need of hair growth inhibition.
- 25. The method of claim 20 wherein said B, T or U is formulated as a cosmetic.
- 26. A method of inhibiting hair loss (alopecia) comprising topical administration of at least one of B, T or U shown in FIG. 1 to a subject undergoing radiation or chemotherapy.
- 27. A method of treating a member selected from the group consisting of fungal, bacterial, viral and parasitic agents, comprising administration of at least one of B, T or U shown in FIG. 1.
- 28. A method according to claim 20 wherein said condition is selected from the group consisting of cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease and inflammatory bowel diseases.
- 29. The polyamine of claim 1 wherein said structure is that of compound Q as shown in FIG. 1.
- 30. The polyamine of claim 1 wherein said structure is that of compound B as shown in FIG. 1.
- 31. The polyamine of claim 1 wherein said structure is that of compound M as shown in FIG. 1.
- 32. The polyamine of claim 1 wherein said structure T as shown in FIG. 1.
- 33. The polyamine of claim 1 wherein said structure U as shown in FIG. 1.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 10/251,819, filed Sep. 23, 2002.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10251819 |
Sep 2002 |
US |
Child |
10810649 |
Mar 2004 |
US |